Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilpivirine - Janssen

Next Previous
Drug Profile

Rilpivirine - Janssen

Alternative Names: Edurant; EDURANTPED; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rekambys; Rilpivirine hydrochloride; TMC 278; TMC-278-A; TMC278 LA (IM injection) - Tibotec; TMC278LA

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen Sciences Ireland UC; Janssen Therapeutics; National Institute of Allergy and Infectious Diseases; PATH; ViiV Healthcare
  • Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in Netherlands (SC, Controlled release)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in USA (SC, Controlled release)
  • 02 Dec 2024 Phase-III clinical trials in HIV-1 infections (Combination therapy, In adolescents, In children, In adults, In the elderly) in Spain and US (IM) (NCT06694805)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top